Hepatitis C treatment outcomes using interferon- and ribavirin-based therapy in Kigali, Rwanda

Conclusions
There were 69 evaluable patients. HCV genotype 4(61%, 42/69) predominated. 24-week SVR was 70%(26/37) by per-protocol and 32%(26/69) by intention-to-treat analysis. HCV treatment in Rwanda is feasible. SVR with interferon/ribavirin was acceptable in the per-protocol analysis. Transition to newer direct acting antivirals is urgently needed in Rwanda and sub-Saharan Africa more generally to improve treatment outcomes.

Source: Transactions of the Royal Society of Tropical Medicine and Hygiene - September 22, 2016 Category: Tropical Medicine Authors: Riedel, D. J., Taylor, S., Simango, R., Kiromera, A., Sebeza, J., Baribwira, C., Musabeyezu, E. Tags: Short Communications Source Type: research